• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

基于多数据库的胶质瘤关键生物标志物及免疫格局模式的识别

Identification of critical biomarkers and immune landscape patterns in glioma based on multi-database.

作者信息

Yuan Hanzhang, Cheng Jingsheng, Xia Jun, Yang Zeng, Xu Lixin

机构信息

Department of Neurosurgery, Yueyang Central Hospital, Yueyang, 414020, Hunan, China.

Department of Neurosurgery, Changde Hospital, Xiangya School of Medicine, Central South University (The First People's Hospital of Changde City), Changde, 415003, Hunan, China.

出版信息

Discov Oncol. 2025 Jan 13;16(1):35. doi: 10.1007/s12672-024-01653-2.

DOI:10.1007/s12672-024-01653-2
PMID:39800804
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11725551/
Abstract

PURPOSE

Glioma is the most prevalent tumor of the central nervous system. The poor clinical outcomes and limited therapeutic efficacy underscore the urgent need for early diagnosis and an optimized prognostic approach for glioma. Therefore, the aim of this study was to identify sensitive biomarkers for glioma.

PATIENTS AND METHODS

Differentially expressed genes (DEGs) of glioma were downloaded from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. The potential biomarkers were identified using weighted gene co-expression network analysis (WGCNA) and least absolute shrinkage and selection operator (LASSO) regression. The prognostic ability of the potential biomarkers was evaluated by Cox regression and survival curve. CellMiner was used to access the correlation between the expression of potential biomarkers and anticancer drug sensitivity. We then explored the association of potential biomarkers and tumor immune infiltration by single-sample GSEA (ssGSEA) and CIBERSORT. Immune staining in glioma patient samples and cell experiments of potential biomarkers further verified their expression and function.

RESULTS

Ultimately, we identified three potential biomarkers: SLC8A2, ATP2B3, and SRCIN1. These 3 genes were found significantly correlated with clinicopathological features (age, WHO grade, IDH mutation status, 1p19q codeletion status). Furthermore, the overall survival (OS), disease-specific survival (DSS), and progression-free survival (PFS) were found to be positively correlated with high expression of these 3 potential biomarkers. Besides, there was a substantial relationship between the sensitivity of anticancer drugs and these biomarkers expression. More importantly, the negative association between the 3 genes with most tumor immune cells was also established. Moreover, the decreased expression of the biomarkers was also verified in glioma patient samples. Finally, we confirmed that these 3 genes might promotes glioma proliferation and migration in vitro.

CONCLUSION

SLC8A2, ATP2B3, and SRCIN1 were identified as underlying biomarkers for glioma associated with prognosis assessments and personal immunotherapy.

摘要

目的

胶质瘤是中枢神经系统最常见的肿瘤。临床预后差和治疗效果有限凸显了对胶质瘤进行早期诊断和优化预后方法的迫切需求。因此，本研究的目的是识别胶质瘤的敏感生物标志物。

患者和方法

从癌症基因组图谱（TCGA）和基因表达综合数据库（GEO）下载胶质瘤的差异表达基因（DEG）。使用加权基因共表达网络分析（WGCNA）和最小绝对收缩和选择算子（LASSO）回归识别潜在的生物标志物。通过Cox回归和生存曲线评估潜在生物标志物的预后能力。使用CellMiner评估潜在生物标志物的表达与抗癌药物敏感性之间的相关性。然后，我们通过单样本基因集富集分析（ssGSEA）和CIBERSORT探索潜在生物标志物与肿瘤免疫浸润的关联。胶质瘤患者样本中的免疫染色和潜在生物标志物的细胞实验进一步验证了它们的表达和功能。

结果

最终，我们确定了三个潜在的生物标志物：SLC8A2、ATP2B3和SRCIN1。发现这三个基因与临床病理特征（年龄、世界卫生组织分级、异柠檬酸脱氢酶（IDH）突变状态、1p19q共缺失状态）显著相关。此外，总生存期（OS）、疾病特异性生存期（DSS）和无进展生存期（PFS）与这三个潜在生物标志物的高表达呈正相关。此外，抗癌药物的敏感性与这些生物标志物的表达之间存在实质性关系。更重要的是，还建立了这三个基因与大多数肿瘤免疫细胞之间的负相关关系。此外，在胶质瘤患者样本中也验证了生物标志物表达的降低。最后，我们证实这三个基因可能在体外促进胶质瘤的增殖和迁移。

结论

SLC8A2、ATP2B3和SRCIN1被确定为与预后评估和个人免疫治疗相关的胶质瘤潜在生物标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/089b/11725551/3a648bf315a2/12672_2024_1653_Fig13_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/089b/11725551/7cd929cf0439/12672_2024_1653_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/089b/11725551/f852b141dc01/12672_2024_1653_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/089b/11725551/dfe8a47319f7/12672_2024_1653_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/089b/11725551/8fb819bb78c3/12672_2024_1653_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/089b/11725551/c7894a3479cd/12672_2024_1653_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/089b/11725551/1e8b6c5de51d/12672_2024_1653_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/089b/11725551/3c704bd64fd1/12672_2024_1653_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/089b/11725551/e9aaa7cebbc2/12672_2024_1653_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/089b/11725551/f31bd64df255/12672_2024_1653_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/089b/11725551/f9c33656e37c/12672_2024_1653_Fig10_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/089b/11725551/305de8e01ce2/12672_2024_1653_Fig11_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/089b/11725551/c76cee3f9509/12672_2024_1653_Fig12_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/089b/11725551/3a648bf315a2/12672_2024_1653_Fig13_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/089b/11725551/7cd929cf0439/12672_2024_1653_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/089b/11725551/f852b141dc01/12672_2024_1653_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/089b/11725551/dfe8a47319f7/12672_2024_1653_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/089b/11725551/8fb819bb78c3/12672_2024_1653_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/089b/11725551/c7894a3479cd/12672_2024_1653_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/089b/11725551/1e8b6c5de51d/12672_2024_1653_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/089b/11725551/3c704bd64fd1/12672_2024_1653_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/089b/11725551/e9aaa7cebbc2/12672_2024_1653_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/089b/11725551/f31bd64df255/12672_2024_1653_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/089b/11725551/f9c33656e37c/12672_2024_1653_Fig10_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/089b/11725551/305de8e01ce2/12672_2024_1653_Fig11_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/089b/11725551/c76cee3f9509/12672_2024_1653_Fig12_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/089b/11725551/3a648bf315a2/12672_2024_1653_Fig13_HTML.jpg

相似文献

1
Identification of critical biomarkers and immune landscape patterns in glioma based on multi-database.基于多数据库的胶质瘤关键生物标志物及免疫格局模式的识别
Discov Oncol. 2025 Jan 13;16(1):35. doi: 10.1007/s12672-024-01653-2.
2
MCM10 as a novel prognostic biomarker and its relevance to immune infiltration in gliomas.MCM10 作为一种新型的预后生物标志物及其与胶质瘤免疫浸润的相关性。
Technol Health Care. 2023;31(4):1301-1317. doi: 10.3233/THC-220576.
3
MELK is a prognostic biomarker and correlated with immune infiltration in glioma.MELK是一种预后生物标志物，与胶质瘤中的免疫浸润相关。
Front Neurol. 2022 Oct 24;13:977180. doi: 10.3389/fneur.2022.977180. eCollection 2022.
4
MCM4 is a novel prognostic biomarker and promotes cancer cell growth in glioma.微小染色体维持蛋白4（MCM4）是一种新型的预后生物标志物，可促进胶质瘤中癌细胞的生长。
Front Oncol. 2022 Nov 17;12:1004324. doi: 10.3389/fonc.2022.1004324. eCollection 2022.
5
EFNA1 is a potential key gene that correlates with immune infiltration in low-grade glioma.EFNA1 是与低级别胶质瘤免疫浸润相关的潜在关键基因。
Medicine (Baltimore). 2021 Jun 4;100(22):e26188. doi: 10.1097/MD.0000000000026188.
6
Identifying as a potential biomarker by the comprehensive exploration of tumor mutational burden and immune infiltration in diffuse large B cell lymphoma.通过全面探索肿瘤突变负担和弥漫性大 B 细胞淋巴瘤中的免疫浸润来鉴定为潜在的生物标志物。
PeerJ. 2023 Dec 11;11:e16618. doi: 10.7717/peerj.16618. eCollection 2023.
7
Next-generation sequencing identifies HOXA6 as a novel oncogenic gene in low grade glioma.下一代测序确定 HOXA6 为低级别胶质瘤中的一种新型致癌基因。
Aging (Albany NY). 2022 Mar 29;14(6):2819-2854. doi: 10.18632/aging.203977.
8
Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.TYROBP 表达升高预示低级别胶质瘤患者预后不良和肿瘤免疫浸润程度高。
BMC Cancer. 2021 Jun 23;21(1):723. doi: 10.1186/s12885-021-08456-6.
9
Functional enrichment analysis of LYSET and identification of related hub gene signatures as novel biomarkers to predict prognosis and immune infiltration status of clear cell renal cell carcinoma.LYSET 功能富集分析及相关枢纽基因特征的鉴定，作为预测透明细胞肾细胞癌预后和免疫浸润状态的新型生物标志物。
J Cancer Res Clin Oncol. 2023 Dec;149(18):16905-16929. doi: 10.1007/s00432-023-05280-2. Epub 2023 Sep 23.
10
Identification of Stemness Characteristics Associated With the Immune Microenvironment and Prognosis in Gastric Cancer.胃癌中与免疫微环境及预后相关的干性特征鉴定
Front Oncol. 2021 Mar 3;11:626961. doi: 10.3389/fonc.2021.626961. eCollection 2021.

本文引用的文献

1
Dynamic Regulation Genes at Microtubule Plus Ends: A Novel Class of Glioma Biomarkers.微管正端的动态调控基因：一类新型的胶质瘤生物标志物。
Biology (Basel). 2023 Mar 22;12(3):488. doi: 10.3390/biology12030488.
2
World Health Organization 2021 Classification of Central Nervous System Tumors and Implications for Therapy for Adult-Type Gliomas: A Review.世界卫生组织 2021 年中枢神经系统肿瘤分类及其对成人型神经胶质瘤治疗的影响：综述。
JAMA Oncol. 2022 Oct 1;8(10):1493-1501. doi: 10.1001/jamaoncol.2022.2844.
3
Differential Gene Expression and Weighted Correlation Network Dynamics in High-Throughput Datasets of Prostate Cancer.
前列腺癌高通量数据集中的差异基因表达与加权相关网络动态
Front Oncol. 2022 Jun 1;12:881246. doi: 10.3389/fonc.2022.881246. eCollection 2022.
4
Genetics of Primary Aldosteronism.原发性醛固酮增多症的遗传学。
Hypertension. 2022 May;79(5):887-897. doi: 10.1161/HYPERTENSIONAHA.121.16498. Epub 2022 Feb 10.
5
Glioma targeted therapy: insight into future of molecular approaches.脑胶质瘤靶向治疗：分子靶向治疗的未来展望。
Mol Cancer. 2022 Feb 8;21(1):39. doi: 10.1186/s12943-022-01513-z.
6
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.2021 年世卫组织中枢神经系统肿瘤分类：概述。
Neuro Oncol. 2021 Aug 2;23(8):1231-1251. doi: 10.1093/neuonc/noab106.
7
PCLasso: a protein complex-based, group lasso-Cox model for accurate prognosis and risk protein complex discovery.PCLasso：一种基于蛋白质复合物的、分组组lasso-Cox 模型，用于准确预测预后和发现风险蛋白复合物。
Brief Bioinform. 2021 Nov 5;22(6). doi: 10.1093/bib/bbab212.
8
Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastoma.血脑屏障的异质性递送限制了 EGFR 靶向抗体药物偶联物在胶质母细胞瘤中的疗效。
Neuro Oncol. 2021 Dec 1;23(12):2042-2053. doi: 10.1093/neuonc/noab133.
9
Gene correlation network analysis to identify regulatory factors in sepsis.基因相关网络分析以识别脓毒症中的调控因子。
J Transl Med. 2020 Oct 8;18(1):381. doi: 10.1186/s12967-020-02561-z.
10
Emerging immunotherapies for malignant glioma: from immunogenomics to cell therapy.恶性神经胶质瘤的新兴免疫疗法：从免疫基因组学到细胞治疗。
Neuro Oncol. 2020 Oct 14;22(10):1425-1438. doi: 10.1093/neuonc/noaa154.